SYRE•benzinga•
Spyre Therapeutics Anticipates Cash Runway Into H2 2028; Expects Phase 1 Results For SPY002 In Q2 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga